Insider Transactions in Q1 2023 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2023
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,282,976
+43.67%
|
-
|
|
Mar 22
2023
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
148,035
+27.01%
|
-
|
|
Mar 22
2023
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
558,094
+39.29%
|
-
|
|
Mar 22
2023
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
558,094
+45.34%
|
-
|
|
Mar 22
2023
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,924,464
+31.45%
|
-
|
|
Mar 14
2023
|
David D Chang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,340
-0.97%
|
$111,700
$5.56 P/Share
|
|
Mar 14
2023
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,879
-10.55%
|
$179,395
$5.47 P/Share
|
|
Mar 14
2023
|
Alison Moore Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,351
-6.79%
|
$41,755
$5.51 P/Share
|
|
Mar 14
2023
|
Veer Bhavnagri General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
23,628
-4.08%
|
$118,140
$5.67 P/Share
|
|
Feb 13
2023
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
3,000
-0.52%
|
$18,000
$6.85 P/Share
|
|
Jan 20
2023
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
251,908
+50.0%
|
-
|
|
Jan 17
2023
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
3,000
-0.51%
|
$21,000
$7.04 P/Share
|